AstraZeneca plc vs Warner Music Group Corp — how do they compare? AstraZeneca plc trades at $167.1 (market cap $253.13B), while Warner Music Group Corp trades at $27.69 (market cap $14.38B). The key difference: AstraZeneca plc is far larger — about 17.6× Warner Music Group Corp's market cap, and Warner Music Group Corp pays the higher dividend (2.76%). Which is the better fit depends on your goals.
| AZN | WMG | |
|---|---|---|
Market Cap | $253.13B | $14.38B |
Sector | Health | Media |
52-Week High | $209.48 | $34.72 |
52-Week Low | $137.44 | $23.65 |
Enterprise Value | $279.37B | $18.58B |
Dividend Yield | 1.92% | 2.76% |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Warner Music Group (WMG) trades at $28.75, down 0.83% today, with a bullish technical signal and strong analyst consensus. Recent financials show revenue growth to $6.71B in 2025, though net income margin declined to 5.44%. The company maintains solid profitability with a 45.8% gross margin and recently acquired AI startup Sureel AI to enhance intellectual property management. Cash flow from operations remains healthy at $678M despite a net cash outflow of $159M in 2025.
WMG offers upside with a $40.40 consensus price target (40.5% potential) and 66.7% buy ratings, supported by streaming growth and AI initiatives. Risks include competitive pressures, margin volatility, and reliance on music industry trends. The stock's high P/E of 34.23 requires sustained earnings acceleration to justify valuation.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →